The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: Results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis

Rheumatology (United Kingdom)

Volumn 55, Issue 11, 2016, Pages 2033-2039

  Silva Fernández, Lucía ^a,b   Lunt, Mark ^a   Kearsley Fleet, Lianne ^a   Watson, Kath D ^a   Dixon, William G ^a,c   Symmons, Deborah P M ^a   Hyrich, Kimme L ^a,c,r   Maiden, Nicola ^d   Price, Tom ^e   Hopkinson, Neil ^f   O'Reilly, Sheila ^g   Hordon, Lesley ^h   Griffiths, Ian ⁱ   Porter, Duncan ^j   Capell, Hilary ^k   Hassell, Andy ^l   Benitha, Romela ^m   Choy, Ernest ⁿ   Walsh, David ^o   Emery, Paul ^p   Knight, Susan ^q   Bruce, Ian ^r   Taggart, Allister ^s   Scott, David ^t   Thompson, Paul ^u   McCrae, Fiona ^v   Goodfellow, Rhian ^w   Kitas, George ^x   Jubb, Ronald ^y   Abernethy, Rikki ^z   Clarke, Shane ^aa   Green, Sandra ^aa   Sanders, Paul ^ab   Coulson, Amanda ^ac   Harrison, Bev ^ad   Bukhari, Marwan ^ae   Klimiuk, Peter ^af   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Servicio de Medicina Interna   (Spain)

^c MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^d ANTRIM AREA HOSPITAL   (United Kingdom)

^e ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

^f CHRISTCHURCH HOSPITAL   (New Zealand)

^g ROYAL DERBY HOSPITAL   (United Kingdom)

^h Dewsbury and District Hospital   (United Kingdom)

ⁱ FREEMAN HOSPITAL   (United Kingdom)

^j GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^k GLASGOW ROYAL INFIRMARY   (United Kingdom)

^l HAYWOOD HOSPITAL   (United Kingdom)

^m HOPE HOSPITAL   (United Kingdom)

ⁿ KING S COLLEGE HOSPITAL   (United Kingdom)

^o Kings Mill Centre ^*  (United Kingdom)

^p LEEDS GENERAL INFIRMARY   (United Kingdom)

^q MACCLESFIELD DISTRICT GENERAL HOSPITAL   (United Kingdom)

^r MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^s MUSGRAVE PARK HOSPITAL   (United Kingdom)

^t NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^u POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^v QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^w ROYAL GLAMORGAN HOSPITAL   (United Kingdom)

^x RUSSELLS HALL HOSPITAL   (United Kingdom)

^y SELLY OAK HOSPITAL   (United Kingdom)

^z St Helens Hospital   (United Kingdom)

^aa WESTON GENERAL HOSPITAL   (United Kingdom)

^ab WITHINGTON HOSPITAL   (United Kingdom)

^ac Withybush General Hospital   (United Kingdom)

^ad NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^ae ROYAL LANCASTER INFIRMARY   (United Kingdom)

^af ROYAL OLDHAM HOSPITAL   (United Kingdom)

more..

Author keywords

Anti TNF; Cancer; Cohort study; Rheumatoid arthritis; Rituximab

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RISK; DISEASE REGISTRY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; NEOPLASM; PRIORITY JOURNAL; RECURRENCE RISK; RHEUMATOID ARTHRITIS; UNITED KINGDOM; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMPLICATION; INCIDENCE; PROSPECTIVE STUDY; RISK FACTOR; TUMOR RECURRENCE;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; FEMALE; HUMANS; INCIDENCE; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS; RITUXIMAB; TUMOR NECROSIS FACTORS; UNITED KINGDOM;

EID: 84997181483     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kew314     Document Type: Article

References (21)

1. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology 2002;16:217-26, 229; discussion 230-2.
2. Abasolo L, Judez E, Descalzo MA et al. Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. Semin Arthritis Rheum 2008;37:388-97.
3. Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther 2015;17:212.
4. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004;50:1740-51.
5. Bongartz T, Warren FC, Mines D et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis 2009;68:1177-83.
6. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis 2009;68:1136-45.
7. Askling J, Fored CM, Brandt L et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1421-6.
8. Mercer LK, Green AC, Galloway JB et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2012;71:869-74.
9. Raaschou P, Simard JF, Holmqvist M, Askling J, Group AS. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ 2013;346:f1939.
10. Dixon WG, Watson KD, Lunt M et al. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res 2010;62:755-63.
11. Strangfeld A, Hierse F, Rau R et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010;12:R5.
12. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927-32.
13. Askling J, Baecklund E, Granath F et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009;68:648-53.
14. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012;308:898-908.
15. Hyrich KL, Watson KD, Isenberg DA, Symmons DP, Register BSRB. The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology 2008;47:1441-3.
16. Mercer LK, Davies R, Galloway JB et al. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology 2013;52:91-8.
17. Mercer LK, Lunt M, Low AL et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2015;74:1087-93.
18. Baecklund E, Iliadou A, Askling J et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701.
19. Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prev 2006;15:2069-77.
20. Hyrich KL, Deighton C, Watson KD et al. Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. Rheumatology 2009;48:1323-7.
21. Soliman MM, Hyrich KL, Lunt M et al. Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register. J Rheumatol 2012;39:240-6.